Cargando…

Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study

Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayet-Roger, Aitana, Joga-Elvira, Lorena, Caixàs, Assumpta, Corripio, Raquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955812/
https://www.ncbi.nlm.nih.gov/pubmed/35329918
http://dx.doi.org/10.3390/jcm11061592
_version_ 1784676428586942464
author Ayet-Roger, Aitana
Joga-Elvira, Lorena
Caixàs, Assumpta
Corripio, Raquel
author_facet Ayet-Roger, Aitana
Joga-Elvira, Lorena
Caixàs, Assumpta
Corripio, Raquel
author_sort Ayet-Roger, Aitana
collection PubMed
description Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.
format Online
Article
Text
id pubmed-8955812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89558122022-03-26 Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study Ayet-Roger, Aitana Joga-Elvira, Lorena Caixàs, Assumpta Corripio, Raquel J Clin Med Article Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels. MDPI 2022-03-14 /pmc/articles/PMC8955812/ /pubmed/35329918 http://dx.doi.org/10.3390/jcm11061592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ayet-Roger, Aitana
Joga-Elvira, Lorena
Caixàs, Assumpta
Corripio, Raquel
Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title_full Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title_fullStr Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title_full_unstemmed Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title_short Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
title_sort cognitive and adaptive effects of early growth hormone treatment in prader–willi syndrome patients: a cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955812/
https://www.ncbi.nlm.nih.gov/pubmed/35329918
http://dx.doi.org/10.3390/jcm11061592
work_keys_str_mv AT ayetrogeraitana cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy
AT jogaelviralorena cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy
AT caixasassumpta cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy
AT corripioraquel cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy